Latest Quetiapine Stories

IRVINE, Calif., Jan. 8, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that Joan E. Shaw, MT (ASCP), SCC has joined the Company as Senior Director of Clinical Operations. "We are pleased to announce that Joan Shaw has recently joined AtheroNova's management team, adding another integral part to the staffing...

WOODCLIFF LAKE, N.J., Oct. 29, 2012 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has entered into an exclusive acquisition and license agreement with Handa Pharmaceuticals, LLC to acquire Handa's Abbreviated New Drug Application (ANDA) for quetiapine fumarate extended-release tablets, the generic version of AstraZeneca's Seroquel XR(®). Handa believes it is the first applicant to file an ANDA containing...

NEW YORK, Aug. 21, 2012 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released second quarter 2012 U.S. prescription sales data for the top 100 drugs. Proton-pump inhibitors, antipsychotics, asthma therapeutics and statins remain the top-selling categories. Plavix and Seroquel dipped in the second quarter due to loss of patent protection. Other top brands such as Singulair, Actos and Diovan are also due to be impacted by year's end. Top Five Drugs...

TORONTO, July 17, 2012 /PRNewswire/ - Scientists have discovered two genetic variants associated with the substantial, rapid weight gain occurring in nearly half the patients treated with antipsychotic medications, according to two studies involving the Centre for Addiction and Mental Health (CAMH). These results could eventually be used to identify which patients have the variations, enabling clinicians to choose strategies to prevent this serious side-effect and offer more...

CHICAGO, April 2, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AstraZeneca (NYSE: AZN), Teva Pharmaceuticals Limited (Nasdaq: TEVA), Mylan Inc. (Nasdaq: MYL), Dr Reddy's Laboratories (NYSE: RDY) and POSCO (NYSE: PKX). (Logo:...

PITTSBURGH, March 28, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Quetiapine Fumarate Tablets, 25 mg. This product is the generic version of AstraZeneca's Seroquel®, which is an atypical antipsychotic medication indicated for the treatment of schizophrenia, and for the treatment of acute manic...

Physicians who prescribe antipsychotic medications may be basing their decisions on incomplete information, according to new research published by scientists at Oregon Health & Science University. The study is published in PLoS Medicine, a peer-reviewed open-access journal published by the Public Library of Science. This latest research follows a highly publicized 2008 report in the New England Journal of Medicine demonstrating that antidepressant drug trials were selectively...

A study in this week's PLoS Medicine suggests that the apparent clinical effectiveness of the newer form of drugs used to treat schizophrenia and other psychotic illnesses (second-generation anti-psychotic drugs) may be enhanced by the selective reporting of trials of these drugs in medical journals – a phenomenon called publication bias. This finding is important as the results of published trials influence clinicians' decisions to prescribe drugs. The authors, led by Erick Turner from...

(Ivanhoe Newswire) – If you’re in pain, there’s a pill for that! But it may not always be good. A new study shows clinical effectiveness of the newer form of drugs used to treat schizophrenia and other psychotic illnesses may be enhanced by a phenomenon called publication bias. The study, led by Erick Turner from Oregon Health & Science University in Portland, shows selective reporting of research results undermines the integrity of the evidence base, which ultimately deprives...

(Ivanhoe Newswire)-- Elderly folks ages 65 and up who are living in a nursing home and taking certain antipsychotic medications for dementia could be hastening their death. The Harvard Medical School undertook the largest study ever among US nursing home residents, researchers looked at 75,445 older nursing home residents from 45 US states between 2001 and 2005. All nursing home residents studied were at least 65 years of age. Risks of mortality were examined over a 6 months period. The...